TGFB1 and breast neoplasm: TGF-β signaling was found to be activated in cells that survived paclitaxel treatment; and combining TGF-β pathway inhibitors with paclitaxel potently prevented recurrences of basal-like breast tumors in vivo (Bhola et al., 2013).